1. Nerlynx
  2. HER2+ / HR+ early breast cancer

EU Healthcare Professionals​

This is an international website for NERLYNX® dedicated to EU Healthcare professionals ​​(outside the UK and ROI).

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that: 

I am a Healthcare Professional in the EU (outside the UK and ROI) and I have read the information above​, the Legal Notice and the Privacy Policy

Patients / Non EU Healthcare Professionals

This is an international website for NERLYNX® dedicated to EU Healthcare Professionals (outside the UK and ROI)

I am a patient or a Healthcare Professional outside the EU.

https://www.pierre-fabre.com/en
Image
heading-Nerlynx-Neratinib--HER2-Breast-Cancer

HER2+ / HR+ early breast cancer

Breast cancer epidemiology

Breast cancer is the most common cancer in women, with more than 2 million new cases each year worldwide.

Amplification or overexpression of HER2 occurs in approximately 15–30% of breast cancers.15

Around 80% of breast cancers test positive for ER, with 65% of these also testing positive for PR.29

Around 10% of breast cancers are HER2+/HR+.30

Breast cancer in females by subtype (%)30 :

Image
eBC epidemiology

After completion of trastuzumab-based therapy, your HER2+/HR+ early breast cancer patients are still at risk of recurrence1-3,6,7,31-36

Without further treatment, 20-30% of patients with HER2+/HR+ disease will experience disease recurrence within 10 years of completing trastuzumab-based therapy. 1-3,6,7,31-36

Residual risk of recurrence for HER2+/HR+ (%) 3 years 5 years 6 years 8 years 10 years
EBCTCG meta-analysis31,a

(adjuvant trastuzumab)		 - 14 - - 20

HERA6,33,b 

(adjuvant trastuzumab)

 10 - - - 28

APHINITY32,34,35,b

(adjuvant trastuzumab + pertuzumab)

 5 - 9
11
 -
KATHERINE7,c

(post-neoadjuvant T-DM1)		 9 - -

-

 -
ExteNET control arm in HER2+/HR+ less than one year since trastuzumab therapy population1,d

(adjuvant trastuzumab)		 - 14 - - -

This table is not direct cross-trial comparisons: direct comparisons cannot be made in the absence of head-to-head trials.

DFS, disease-free survival; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor positive; T-DM1, trastuzumab emtasine.

a Recurrence refers to DFS, defined as the time from enrolment to documentation of the first of any of these events: local, regional or distant recurrence of breast cancer; a new primary contralateral breast cancer.31

b Recurrence refers to DFS, defined as the time from randomisation to the first occurrence of any of these events: recurrence of breast cancer at any site; the development of ipsilateral or contralateral breast cancer, including ductal carcinoma in situ but not lobular carcinoma in situ; second non-breast malignant disease other than basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix; or death from any cause.36

c Recurrence refers to iDFS, defined as time from randomisation to the first occurrence of any of the following events: recurrence of ipsilateral invasive breast tumour, recurrence of ipsilateral locoregional invasive breast cancer, contralateral invasive breast cancer, a distant disease recurrence or death from any cause.7,34

d Recurrence defined as the first occurrence of any of the following events: recurrence of ipsilateral invasive breast tumour, recurrence of ipsilateral locoregional invasive breast cancer, contralateral invasive breast cancer, a distant disease recurrence, or death from any cause.

Learn about…

NERLYNX
Efficacy

Image
Nerlynx-Neratinib--Read-Also

NERLYNX
Safety

Image
Nerlynx-Neratinib--Read-Also

NERLYNX
Dosing

Image
Nerlynx-Neratinib--Read-Also